Sort   by:  
 Page size 
Genomicsena-DATASET-MGH-10-02-2015-15:19:45:352-2 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. WG sequencing produced ~30-fold (primary tumour, spleen normal)-50-fold (lung metastasis) coverage
EGAD00001001253 | EGA
Genomicsena-DATASET-MGH-10-02-2015-15:17:58:985-1 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. For WE sequencing we user Hybrid capture (Nimblegen version 3.0) of the lymph node and lung metastases, primary tumour and spleen normal; we generated ~1...
EGAD00001001252 | EGA
GenomicsTherapeutic Resistance to PI3K-alpha Inhibitors
We have studied the tumor genomic evolution in a patient with metastatic breast cancer bearing an activating PIK3CA mutation. The patient was treated with the PI3Kα inhibitor BYL719 and achieved a lasting clinical response on BYL719, but eventually progressed to treatment and died shortly thereafter...
EGAS00001000991 | EGA
GenomicsMemorial Sloan Kettering Cancer Center - Human Oncology & Pathogenesis Program (HOOP) - Data Access Committee
Data Access Committee EGAC00001000305
EGAC00001000305 | EGA
Genomicsena-DATASET-MGH-CC-08-07-2015-20:42:52:693-393 - samples
Description not provided
EGAD00001001436 | EGA
GenomicsRB Loss in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to Small Cell Lung Cancer
Tyrosine kinase inhibitors (TKIs) are effective treatments for non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, they do not lead to cures, and, on average, relapse occurs typically occurs afterafter an average of one year of continuous treatment....
EGAS00001001102 | EGA
GenomicsMGH Thoracic Oncology
Data Access Committee EGAC00001000284
EGAC00001000284 | EGA
Sort   by:  
 Page size